Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallenge.
Qin T, Mattox AK, Campbell JS, Park JC, Shin KY, Li S, Sadow PM, Faquin WC, Micevic G, Daniels AJ, Haddad R, Garris CS, Pittet MJ, Mempel TR, ONeill A, Sartor MA, Pai SI.
Qin T, et al. Among authors: campbell js.
J Clin Invest. 2025 Mar 17;135(6):e181671. doi: 10.1172/JCI181671.
J Clin Invest. 2025.
PMID: 40091844
Free PMC article.
Clinical Trial.